Search

Your search keyword '"Kim, Dennis Dong Hwan"' showing total 911 results
Start Over Author "Kim, Dennis Dong Hwan"
911 results on '"Kim, Dennis Dong Hwan"'

252. Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant

Author

Ahn, Jae-Sook, primary, Kim, Jae-Yong, additional, Kim, Hyeoung-Joon, additional, Kim, Yeo-Kyeoung, additional, Lee, Seung-Shin, additional, Jung, Sung-Hoon, additional, Yang, Deok-Hwan, additional, Lee, Je-Jung, additional, Kim, Nan Young, additional, Choi, Seung Hyun, additional, Minden, Mark D., additional, Jung, Chul Won, additional, Jang, Jun-Ho, additional, Kim, Hee Je, additional, Moon, Joon Ho, additional, Sohn, Sang Kyun, additional, Won, Jong-Ho, additional, Kim, Sung-Hyun, additional, and Kim, Dennis Dong Hwan, additional

Published
2015
Full Text
View/download PDF

254. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.

Author

Park, Silvia, Choi, Hangseok, Kim, Hee Je, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Kim, Sung-Hyun, Mun, Yeung-Chul, Jung, Chul Won, and Kim, Dennis (Dong Hwan)

Subjects
ACUTE myeloid leukemia treatment, ACUTE myeloid leukemia diagnosis, STEM cell transplantation, ALLELES, BIOLOGICAL models, DRUG therapy, COMBINED modality therapy, GENES, GENETIC polymorphisms, LONGITUDINAL method, MORTALITY, PROGNOSIS, SURVIVAL analysis (Biometry), ACUTE myeloid leukemia, SEQUENCE analysis
Abstract

The present study attempted to build a single nucleotide polymorphism (SNP)-based risk model for predicting overall survival (OS) and event-free survival (EFS) in patients with core binding factor acute myeloid leukemia (CBF-AML). Adopting genome-wide SNP array using Affymetrix SNP array 6.0, we analyzed 868,157 SNPs with respect to OS and EFS in 104 patients with CBF-AML. Significant SNPs were identified from single SNP analysis. The risk model was constructed with incorporation of six SNPs and three clinical factors (age, c-kit exon 17 mutation, and LDH) for OS and six SNPs and three clinical factors (age, WBC, and LDH) for EFS. The model was further defined into low- and high-risk groups based on risk scores. The median age was 39 years, and the subgroup of t(8;21) and inv(16) or t(16;16) was assessed in 68 (65.4%) and 36 patients (34.6%). Finally, six SNPs per each OS (rs4353685, rs4908185, rs7709207, rs12034, rs1554844, and rs17241868) and EFS (rs13385610, rs11210617, rs11169282, rs7709207, rs4438401, and rs16894846) were incorporated into the risk model. OS was significantly different in favor of the low risk group (80.4 ± 8.4%) compared to the high-risk group (22.0 ± 7.3% at 3 years; p = 8.75 × 10- 13; HR 8.67). For EFS, there was also a significant difference between the low- (75.0 ± 5.8%) versus high-risk group (17.1 ± 6.3% at 3 years; p = 5.95 × 10- 13; HR 7.67). A genome-wide SNP-based risk model can stratify CBF-AML patients according to their OS and EFS in 104 patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

255. Outcome following second allogeneic hematopoietic cell transplantation: A single‐center experience.

Author

Aljasem, Hassan A., Messner, Hans A., Lipton, Jeffrey H., Kim, Dennis Dong Hwan, Viswabandya, Auro, Thyagu, Santhosh, Deotare, Uday, and Michelis, Fotios V.

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT rejection, ACUTE myeloid leukemia, NEUTROPENIA, CYCLOSPORINE
Abstract

Abstract: Objective: Second allogeneic hematopoietic cell transplantation (HCT) may be indicated following relapse or graft failure following first HCT. Our retrospective single‐center study sought to investigate parameters that influence post‐second allogeneic HCT survival. Method: We investigated 92 patients who underwent second allogeneic HCT between 1980 and 2016 for relapse or graft failure following first HCT. Median age at second HCT was 41 years (range 16‐68), performed for relapse in 59 patients (64%) and for graft failure in 33 patients (36%). Results: On univariate analysis, 3‐year OS of the entire cohort was 35% (95% CI=25‐45). Eastern Cooperative Oncology Group (ECOG) score (3‐year OS 48% for ECOG 0‐1, 18% for ECOG 2‐3, P=.0006), second HCT indication (3‐year OS 43% for relapse, 20% for graft failure, P=.02), time from first HCT to relapse/graft failure (3‐year OS for <12months 21%, for ≥12months 46%, P=.009), and conditioning intensity (3‐year OS for MA 42% vs other regimens 23%, P=.08) significantly influenced OS. Multivariable analysis confirmed ECOG score (HR=2.15 for ECOG 2‐3, 95% CI=1.32‐3.51, P=.002) and second HCT indication (HR=1.67 for graft failure, 95% CI=1.02‐2.75, P=.04) to independently influence survival. Conclusion: Second HCT may offer long‐term survival particularly to patients with good performance status who relapse post‐first HCT. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

256. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

Author

Park, Jong-Ho, Woo, Young Min, Youm, Emilia Moonkyung, Hamad, Nada, Won, Hong-Hee, Naka, Kazuhito, Park, Eun-Ju, Park, June-Hee, Kim, Hee-Jin, Kim, Sun-Hee, Kim, Hyeoung-Joon, Ahn, Jae Sook, Sohn, Sang Kyun, Moon, Joon Ho, Jung, Chul Won, Park, Silvia, Lipton, Jeffrey H., Kimura, Shinya, Kim, Jong-Won, and Kim, Dennis (Dong Hwan)

Abstract

Achieving a deep molecular response (DMR) to tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) remains challenging and at present, there is no biomarker to predict DMR in this setting. Herein, we report that an HMGCLL1genetic variant located in 6p12.1 can be used as a predictive genetic biomarker for intrinsic sensitivity to imatinib (IM) therapy. We measured DMR rate according to HMGCLL1variant in a discovery set of CML patients (n= 201) and successfully replicated it in a validation set (n= 270). We also investigated the functional relevance of HMGCLL1blockade with respect to response to TKI therapy and showed that small interfering RNA mediated blockade of HMGCLL1isoform 3 results in significant decrease in viability of BCR-ABL1-positive cells including K562, CML-T1 or BaF3 cell lines with or without ABL1kinase domain mutations such as T315I mutation. Decreased cell viability was also demonstrated in murine CML stem cells and human hematopoietic progenitor cells. RNA sequencing showed that blockade of HMGCLL1was associated with G0/G1 arrest and the cell cycle. In summary, the HMGCLL1gene polymorphism is a novel genetic biomarker for intrinsic sensitivity to IM therapy in CML patients that predicts DMR in this setting.

Published
2019
Full Text
View/download PDF

257. DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant.

Author

Khaire, Niranjan Shiwaji, Kim, Dennis Dong Hwan, and Law, Arjun D.

Subjects
*ACUTE myeloid leukemia, *DNA sequencing, *ADULTS, *PRELEUKEMIA
Abstract

Comment & Response B To the Editor b A recent study[1] showed pretransplant persistence of I FLT3 i internal tandem duplication ( I FLT3 i -ITD) and I NPM1 i variants in adults with acute myeloid leukemia (AML) to be an effective predictor of posttransplant relapse. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. [Extracted from the article]

Published
2023
Full Text
View/download PDF

260. Propensity Score Matching Comparing Asciminib VersusPonatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Author

Perusini, Maria Agustina, Kockerols, Camille, Žáčková, Daniela, Nicolini, Franck E., Castagnetti, Fausto, Pavlovsky, Carolina, Breccia, Massimo, Rea, Delphine, Fava, Carmen, Savoie, Mary Lynn, Bouvier, Christophe, Čičátková, Petra, Bollard, Julien, Linn, Swe Mar, Gupta, Gopila, Scalzulli, Emilia, Mayer, Jiří, Westerweel, Peter E, and Kim, Dennis Dong Hwan

Abstract

Background

Published
2023
Full Text
View/download PDF

261. Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Author

Lucero, Josephine Anne, Bankar, Aniket, Davidson, Marta Beata, Richard-Carpentier, Guillaume, Schimmer, Aaron D., Schuh, Andre C., Maze, Dawn C., Yee, Karen, Minden, Mark D., Chan, Steven M., Mattsson, Jonas, Kumar, Rajat, Gupta, Vikas, Capo-Chichi, Jose-Mario, Stockley, Tracy, Sibai, Hassan, Tierens, Anne Maria, and Kim, Dennis Dong Hwan

Abstract

Introduction

Published
2023
Full Text
View/download PDF

263. The Presence of Somatic Mutations on Specific Pathways Such As Chromatin Modifier, Spliceosome, and Myeloid Transcription Factor at Diagnosis Was Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in 1,228 Patients with Acute Myeloid Leukemia in First Complete Remission (CR1)

Author

Sayyed, Ayman, Kim, Taehyung Simon, Park, Silvia, Ahn, Jae-Sook, Karsan, Aly, Gagnon, Marie-France, Bergeron, Julie, Kim, Hyeoung-Joon, Kim, Heeje, Sanford, David, Schuh, Andre C., and Kim, Dennis Dong Hwan

Abstract

Introduction

Published
2023
Full Text
View/download PDF

264. Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Author

Mauro, Michael, Minami, Yosuke, Hochhaus, Andreas, Lomaia, Elza, Voloshin, Sergei, Turkina, Anna, Kim, Dong-Wook, Apperley, Jane F, Cortes, Jorge, Abdo, Andre N.R., Fogliatto, Laura Maria, Kim, Dennis Dong Hwan, le Coutre, Philipp, Saussele, Susanne, Annunziata, Mario, Hughes, Timothy P, Chaudhri, Naeem A., Chee, Lynette C.Y., García Gutiérrez, Valentín, Sasaki, Koji, Boquimpani De Moura Freitas, Carla Maria, Kapoor, Shruti, Espurz, Noemi, Dhamal, Vishal, and Rea, Delphine

Abstract

CML requires chronic therapy, emphasizing the need for Txs that are characterized by high, durable efficacy and a low adverse event (AE) burden. ASC, the first BCR::ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), demonstrated significantly superior efficacy and better safety/tolerability compared with BOS in pts with CML-CP who received ≥2 prior TKIs in the phase 3 ASCEMBL study. Major molecular response (MMR) rate was 25.5% with ASC vs 13.2% with BOS at wk 24, meeting the primary objective, and 37.6% vs 15.8% at wk 96, meeting the key secondary objective. Despite the longer duration of exposure to ASC, safety/tolerability remained consistently better with ASC vs BOS, with fewer all-grade and grade ≥3 AEs and AEs leading to Tx discontinuation observed.

Published
2023
Full Text
View/download PDF

265. New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Author

Gupta, Gopila, Chiu, May, Al-Shaibani, Eshrak, Perusini, Maria Agustina, Lucero, Josephine, Zackova, Daniela, Jeziskova, Ivana, Kvetkova, Anezka, Jurcek, Tomas, Kim, Jaeyoon John, Pyne, Danielle, Travas, Anthea, Ambalavanan, Amirthagowri, Mayer, Jiri, Medeiros, Jessie, Abelson, Sagi, and Kim, Dennis Dong Hwan

Abstract

Introduction

Published
2023
Full Text
View/download PDF

266. The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Author

Sayyed, Ayman, Lee, Hyewon, Kim, Taehyung Simon, Kim, Jaeyoon John, Pyne, Danielle, Kaushansky, Nathali, Brilon, Yardena, Chapal-Ilani, Noa, Biezuner, Tamir, Shlush, Liran I., Storek, Jan, and Kim, Dennis Dong Hwan

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

267. Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Author

Bhatti, Muzaffar, Kim, Taehyung, Warrington, Jenny, Ambalavanan, Amirthagowri, Zarabi, Sarah, Travas, Anthea, Kim, Jaeyoon John, Pyne, Danielle, Ketela, Troy, Arruda, Andrea, Minden, Mark D., Keating, Armand, and Kim, Dennis Dong Hwan

Abstract

Introduction:Acute myeloid leukemia (AML) involves somatic mutations in hematopoietic stem cells (HSCs). Recent evidence suggests the bone marrow microenvironment, particularly mesenchymal stromal cells (MSCs), also influences AML development. Abnormalities in MSCs from AML patients have been observed (von der Heide et al., 2016), potentially impacting leukemia progression. This study aims to identify MSC somatic mutations and their consequences, further exploring their role in AML. Understanding MSCs' impact on the leukemic microenvironment may shed light on AML pathophysiology and guide targeted therapies, particularly benefiting patients with adverse risk disease.

Published
2023
Full Text
View/download PDF

270. Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Author

Alfaro, Tommy, Salas, Maria Queralt, Atenafu, Eshetu, Bascom, Ora, Wilson, Leeann, Chen, Carol, Law, Arjun D., Gerbitz, Armin, Viswabandya, Auro, Michelis, Fotios, Lipton, Jeffrey H., Lam, Wilson, Novitzky-Basso, Igor, Kim, Dennis (Dong Hwan) Dong Hwan, Mattsson, Jonas, Pasic, Ivan, and Kumar, Rajat

Abstract

Background: We demonstrated that impaired functionality and frailty have a negative impact on survival after allogeneic hematopoietic cell transplantation (HCT) (Salas et al., 2019). This impact is independent of other predictive models including HCT comorbidity index (HCT-CI) and disease risk index (DRI). Cognitive changes are frequently reported among survivors of autologous and allogeneic HCT. However, impact of the presence of cognitive impairment prior to allogeneic HCT has not been studied. We hypothesized that the presence of cognitive impairment before transplantation could have a negative effect on the outcomes of allogeneic HCT.

Published
2023
Full Text
View/download PDF

271. Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Author

Perusini, Maria Agustina, Pagnano, Katia, Pavlovsky, Carolina, Moiraghi, Beatriz, Varela, Ana, Bianchini, Michele, Fava, Carmen, Mayer, Jiří, Žáčková, Daniela, Kvetková, Anežka, Jurček, Tomáš, Ježíšková, Ivana, Lopes, Ana Beatriz Pascoal, Oliveira, Gislaine Borba, De Souza, Carmino, Ambalavanan, Amirthagowri, Travas, Anthea, Kim, Jaeyoon John, Pyne, Danielle, Medeiros, Jessie, Abelson, Sagi, and Kim, Dennis Dong Hwan

Abstract

Background

Published
2023
Full Text
View/download PDF

272. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant

Author

Ahn, Jae-Sook, primary, Kim, Jae-Young, additional, Kim, Hyeoung-Joon, additional, Kim, Yeo-Kyeoung, additional, Lee, Seung-Shin, additional, Jung, Sung-Hoon, additional, Yang, Deok-Hwan, additional, Lee, Je-Jung, additional, Kim, Nan Young, additional, Choi, Seung Hyun, additional, Minden, Mark D., additional, Jung, Chul Won, additional, Jang, Jun-Ho, additional, Kim, Hee Je, additional, Moon, Joon Ho, additional, Sohn, Sang Kyun, additional, Won, Jong-Ho, additional, Kim, Sung-Hyun, additional, and Kim, Dennis Dong Hwan, additional

Published
2015
Full Text
View/download PDF

274. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score

Author

Michelis, Fotios V., primary, Messner, Hans A., additional, Uhm, Jieun, additional, Alam, Naheed, additional, Lambie, Anna, additional, McGillis, Laura, additional, Seftel, Matthew D., additional, Gupta, Vikas, additional, Kuruvilla, John, additional, Lipton, Jeffrey H., additional, and Kim, Dennis (Dong Hwan), additional

Published
2015
Full Text
View/download PDF

275. Mycophenolate‐based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative‐related donor stem cell transplantation

Author

Hamad, Nada, primary, Shanavas, Mohamed, additional, Michelis, Fotios V., additional, Uhm, Jieun, additional, Gupta, Vikas, additional, Seftel, Matthew, additional, Kuruvilla, John, additional, Lipton, Jeffrey H., additional, Messner, Hans A., additional, and Kim, Dennis (Dong Hwan), additional

Published
2015
Full Text
View/download PDF

279. A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Author

Alfraih, Feras, primary, Kuruvilla, John, additional, Alam, Naheed, additional, Lambie, Anna, additional, Gupta, Vikas, additional, Kim, Dennis Dong Hwan, additional, Seftel, Matthew D., additional, Uhm, Jieun, additional, Loach, David, additional, Atenafu, Eshetu G, additional, Lipton, Jeffrey H., additional, and Messner, Hans A., additional

Published
2014
Full Text
View/download PDF

281. Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen

Author

Sibai, Hassan, primary, Michelis, Fotios V., additional, Hamad, Nada, additional, Uhm, Jieun, additional, Gupta, Vikas, additional, Kuruvilla, John G., additional, Lipton, Jeffrey H., additional, Messner, Hans A., additional, Seftel, Matthew D., additional, and Kim, Dennis Dong Hwan, additional

Published
2014
Full Text
View/download PDF

282. Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Author

Alfraih, Feras, primary, Alam, Naheed, additional, Gupta, Vikas, additional, Kim, Dennis Dong Hwan, additional, Kuruvilla, John, additional, Lipton, Jeffrey H., additional, Loach, David, additional, Seftel, Matthew D., additional, Uhm, Jieun, additional, Lambie, Anna, additional, and Messner, Hans A., additional

Published
2014
Full Text
View/download PDF

284. An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype

Author

Ahn, Jae-Sook, primary, Kim, Hyeoung-Joon, additional, Kim, Yeo-Kyeoung, additional, Lee, Il-Kwon, additional, Kim, Nan Young, additional, Minden, Mark D, additional, Jung, Chul Won, additional, Jang, Jun-Ho, additional, Kim, Hee-Je, additional, Moon, Joon Ho, additional, Sohn, Sang Kyun, additional, Won, Jong-Ho, additional, Kim, Sung-Hyun, additional, Kim, Namshin, additional, Yoshida, Kenichi, additional, Ogawa, Seishi, additional, and Kim, Dennis Dong Hwan, additional

Published
2014
Full Text
View/download PDF

287. Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.

Author

Herrity, Elizabeth, Pereira, Mariana Pinto, and Kim, Dennis Dong Hwan

Subjects
*HEMATOPOIETIC stem cell transplantation, *ACUTE myeloid leukemia, *T-cell exhaustion, *STEM cell transplantation, *IMMUNE checkpoint proteins
Abstract

Summary: Emerging biological and clinical data, along with advances in new technologies, have exposed the mechanistic diversity in post‐haematopoietic stem cell transplant (HCT) relapse. Post‐HCT relapse mechanisms are relevant for guiding sophisticated selection of therapeutic interventions and identification of areas for further research. Clonal evolution and emergence of resistant leukemic strains is a common mechanism shared by relapse post‐chemotherapy and post‐HCT, other mechanisms such as leukemic immune escape and donor T cell exhaustion are unique entities to post‐HCT relapse. Due to diversity in the mechanisms behind post‐HCT relapse, the subsequent clinical approach relies on clinician discretion, rather than objective evidence. Lack of standardized selection based on post‐HCT relapse mechanism(s) could be a contributing factor to observed poor outcomes. Therapeutic strategies including donor lymphocyte infusion (DLI), second transplant, immunotherapies, hypomethylating agents, and targeted strategies are supported options and efficacy may be enhanced when post‐HCT AML relapse mechanism is established and guides treatment selection. This review aims, through compilation of supporting studies, to describe mechanisms of post‐HCT relapse and their implications for subsequent treatment selection and inspiration for future research. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

288. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.

Author

Moon, Joon, Hamad, Nada, Sohn, Sang, Uhm, Jieun, Alam, Naheed, Gupta, Vikas, Lipton, Jeffrey, Messner, Hans, Seftel, Matthew, Kuruvilla, John, Kim, Dennis, Moon, Joon Ho, Sohn, Sang Kyun, Lipton, Jeffrey H, Messner, Hans A, and Kim, Dennis Dong Hwan

Subjects
GRAFT versus host disease, STEM cell transplantation, SURVIVAL analysis (Biometry), MORTALITY, LYMPHOCYTE count
Abstract

The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). The 3-year overall survival (OS) rates in each risk group (RG) were 82.5 ± 11.3% (RG1), 79.4 ± 3.0% (RG2), 71.8 ± 6.3% (RG3), and 27.3 ± 13.4% (RG4). A significantly lower OS rate and higher non-relapse mortality (NRM) were noted in RG4 compared to the other RGs. However, there were no differences in OS or NRM among RG1 to 3. To improve prognostic stratification power of the CIBMTR risk score, we incorporated the absolute lymphocyte (ALC) and eosinophil count (EC) at time of cGVHD into the CIBMTR risk score. Lower ALC (<1.0 × 109/L, HR 1.94, p = 0.014) and lower EC (<0.5 × 109/L, HR 3.27, p = 0.014) were confirmed as adverse risk factors for OS. Patients were stratified into four revised risk groups (rRG). The 3-year OS rates were 93.3 ± 6.4% (rRG1, score 0-3), 84.9 ± 3.4% (rRG2, score 4-6), 70.9 ± 4.4% (rRG3, score 7-9), and 32.0 ± 1.1% (rRG4, score ≥ 10) (p < 0.001). The 3-year NRM rates were 0.0% (rRG1), 6.7 ± 0.4% (rRG2), 18.4 ± 0.7% (rRG3), and 57.7 ± 5.1% (rRG4) (p < 0.001). The revised CIBMTR risk score was superior to the original CIBMTR risk score for OS (p < 0.001). The revised CIBMTR risk score including ALC and EC at the onset of cGVHD improved the prognostic stratification power of the CIBMTR risk score for long-term outcomes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

290. Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Author

Uhm, Jieun, primary, Hamad, Nada, additional, Shin, Elizabeth M., additional, Michelis, Fotios V., additional, Shanavas, Mohamed, additional, Gupta, Vikas, additional, Kuruvilla, John, additional, Lipton, Jeffrey H., additional, Messner, Hans A., additional, Seftel, Matthew, additional, and Kim, Dennis (Dong Hwan), additional

Published
2014
Full Text
View/download PDF

292. Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response

Author

Shanavas, Mohamed, primary, Messner, Hans A., additional, Kamel-Reid, Suzanne, additional, Atenafu, Eshetu G., additional, Gupta, Vikas, additional, Kuruvilla, John, additional, Kim, Dennis (Dong Hwan), additional, Uhm, Jieun, additional, Lambie, Anna, additional, Ellis, Laura, additional, and Lipton, Jeffrey H., additional

Published
2014
Full Text
View/download PDF

293. A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation

Author

Shanavas, Mohamed, primary, Messner, Hans A., additional, Kamel-Reid, Suzanne, additional, Atenafu, Eshetu G., additional, Gupta, Vikas, additional, Kuruvilla, John, additional, Kim, Dennis (Dong Hwan), additional, Uhm, Jieun, additional, Lambie, Anna, additional, Ellis, Laura, additional, and Lipton, Jeffrey H., additional

Published
2014
Full Text
View/download PDF

295. Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Author

Kim, TaeHyung, Moon, Joon Ho, Ahn, Jae-Sook, Kim, Yeo-Kyeoung, Lee, Seung-Shin, Ahn, Seo-Yeon, Jung, Sung-Hoon, Yang, Deok-Hwan, Lee, Je-Jung, Choi, Seung Hyun, Lee, Ja-yeon, Tyndel, Marc S., Shin, Myung-Geun, Lee, Yoo Jin, Sohn, Sang Kyun, Park, Seong-Kyu, Zhang, Zhaolei, Kim, Hyeoung-Joon, and Kim, Dennis Dong Hwan

Abstract

Next-generation sequencing (NGS) has been applied to define clinically relevant somatic mutations and classify subtypes in acute myeloid leukemia (AML). Persistent allelic burden after chemotherapy is associated with higher relapse incidence, but presence of allelic burden in AML patients after receiving allogeneic hematopoietic cell transplantation (HCT) has not been examined longitudinally. As such, we aimed to assess the feasibility of NGS in monitoring AML patients receiving HCT. Using a targeted gene panel, we performed NGS in 104 AML patients receiving HCT using samples collected at diagnosis, pre-HCT, and post-HCT at day 21 (post-HCTD21). NGS detected 256 mutations in 90 of 104 patients at diagnosis, which showed stepwise clearances after chemotherapy and HCT. In a subset of patients, mutations were still detectable pre-HCT and post-HCT. Most post-HCT mutations originate from mutations initially detected at diagnosis. Post-HCTD21 allelic burdens in relapsed patients were higher than in nonrelapsed patients. Post-HCTD21 mutations in relapsed patients all expanded at relapse. Assessment of variant allele frequency (VAF) revealed that overall VAF post-HCTD21 (VAF0.2%-post-HCTD21) is associated with an increased risk of relapse (56.2% vs 16.0% at 3 years; P < .001) and worse overall survival (OS; 36.5% vs 67.0% at 3 years; P = .006). Multivariate analyses confirmed that VAF0.2%-post-HCTD21 is an adverse prognostic factor for OS (hazard ratio [HR], 3.07; P = .003) and relapse incidence (HR, 4.75; P < .001), independent of the revised European LeukemiaNet risk groups. Overall, current study demonstrates that NGS-based posttransplant monitoring in AML patients is feasible and can distinguish high-risk patients for relapse.

Published
2018
Full Text
View/download PDF

297. The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Author

Perusini, Maria Agustina, Kim, Taehyung Simon, Žácková, Daniela, Pagnano, Katia B, Mayer, Jiří, Pavlovsky, Carolina, Ježíšková, Ivana, Kvetková, Anežka, Jurček, Tomáš, Moiraghi, Beatriz, Varela, Ana Ines, Bianchini, Michele, Lopes, Ana Beatriz Pascoal, Duarte, Gislaine B O, Yoo, Young Seok, Souza, Carmino Antonio, Medeiros, Jessie, Lee, Hye Won, Kim, Kyoung Ha, Yi, Seong Yoon, Chang, Myung Hee, Abelson, Sagi, and Kim, Dennis Dong Hwan

Published
2022
Full Text
View/download PDF

300. Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Author

Perusini, Maria Agustina, Atenafu, Eshetu G., Forrest, Donna L., Isabelle, Bence-Bruckler, Savoie, Lynn, Keating, Mary-Margaret, Busque, Lambert, Delage, Robert, Xenocostas, Anargyros, Liew, Elena, Laneuville, Pierre, Paulson, Kristjan, Stockley, Tracy L., Lipton, Jeffrey H., Leber, Brian, and Kim, Dennis Dong Hwan

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results